GSK sales fall 8 pct, hit by weak Europe and vaccines
LONDON Oct 31 (Reuters) - GlaxoSmithKline sales fell 8 percent in the third quarter, hurt by continued pressure on drug prices in austerity-hit Europe and lower demand for vaccines compared to a year ago.
Sales of 6.53 billion pounds ($10.50 billion) generated "core" earnings per share (EPS) down 13 percent at 26.5 pence, as Britain's biggest drugmaker suffered another tough quarter.
Analysts, on average, had forecast sales of 6.67 billion pounds and core EPS, which excludes certain items, of 27.8p, according to Thomson Reuters I/B/E/S.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Target holiday cyber breach hits 40 million payment cards |
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion |
- Special Report: Why Ukraine spurned the EU and embraced Russia